Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Split-Luciferase-Based Trimer Formation Assay as a High-throughput Screening Platform for Therapeutics in Alport Syndrome.
Omachi K, Kamura M, Teramoto K, Kojima H, Yokota T, Kaseda S, Kuwazuru J, Fukuda R, Koyama K, Matsuyama S, Motomura K, Shuto T, Suico MA, Kai H. Omachi K, et al. Among authors: kaseda s. Cell Chem Biol. 2018 May 17;25(5):634-643.e4. doi: 10.1016/j.chembiol.2018.02.003. Epub 2018 Mar 8. Cell Chem Biol. 2018. PMID: 29526710 Free article.
Metformin ameliorates the severity of experimental Alport syndrome.
Omachi K, Kaseda S, Yokota T, Kamura M, Teramoto K, Kuwazuru J, Kojima H, Nohara H, Koyama K, Ohtsuki S, Misumi S, Takeo T, Nakagata N, Li JD, Shuto T, Suico MA, Miner JH, Kai H. Omachi K, et al. Among authors: kaseda s. Sci Rep. 2021 Mar 29;11(1):7053. doi: 10.1038/s41598-021-86109-1. Sci Rep. 2021. PMID: 33782421 Free PMC article.
Novel Keap1-Nrf2 Protein-Protein Interaction Inhibitor UBE-1099 Ameliorates Progressive Phenotype in Alport Syndrome Mouse Model.
Kaseda S, Sannomiya Y, Horizono J, Kuwazuru J, Suico MA, Ogi S, Sasaki R, Sunamoto H, Fukiya H, Nishiyama H, Kamura M, Niinou S, Koyama Y, Nara F, Shuto T, Onuma K, Kai H. Kaseda S, et al. Kidney360. 2021 Dec 1;3(4):687-699. doi: 10.34067/KID.0004572021. eCollection 2022 Apr 28. Kidney360. 2021. PMID: 35721612 Free PMC article.
CyclosporinA Derivative as Therapeutic Candidate for Alport Syndrome by Inducing Mutant Type IV Collagen Secretion.
Kuwazuru J, Suico MA, Omachi K, Kojima H, Kamura M, Kaseda S, Kawahara T, Hitora Y, Kato H, Tsukamoto S, Wada M, Asano T, Kotani S, Nakajima M, Misumi S, Sannomiya Y, Horizono J, Koyama Y, Owaki A, Shuto T, Kai H. Kuwazuru J, et al. Among authors: kaseda s. Kidney360. 2023 Jul 1;4(7):909-917. doi: 10.34067/KID.0000000000000134. Epub 2023 May 5. Kidney360. 2023. PMID: 37143203 Free PMC article.
Trimerization profile of type IV collagen COL4A5 exon deletion in X-linked Alport syndrome.
Koyama Y, Suico MA, Owaki A, Sato R, Kuwazuru J, Kaseda S, Sannomiya Y, Horizono J, Omachi K, Horinouchi T, Yamamura T, Tsuhako H, Nozu K, Shuto T, Kai H. Koyama Y, et al. Among authors: kaseda s. Clin Exp Nephrol. 2024 Sep;28(9):874-881. doi: 10.1007/s10157-024-02503-9. Epub 2024 Apr 24. Clin Exp Nephrol. 2024. PMID: 38658441
123 results